1. Scrip
  2. >>Business

Revlimid Generic Revs Up Dr Reddy’s To Record Gains, There’s More To Come

 
• By Anju Ghangurde

Generic Revlimid US sales propel Dr Reddy’s to a record fiscal second quarter, with the management indicating that “meaningful” contributions are likely in the coming months too. The Indian firm also expects to deploy its healthy cash flows for deal-making, aided by tempered valuations in some segments amid geopolitical and economic turbulence.

Revlimid Generic Propels Sharp Earnings Delta For Dr Reddy's • Source: Shutterstock

Generic Revlimid (lenalidomide) brought extended festive season cheer to Dr. Reddy's Laboratories Ltd.'s investors after the Indian firm’s earnings rose sharply in the fiscal second quarter buoyed by US sales of the cancer therapy.

While Dr Reddy’s declined to specify the actual contribution of lenalidomide to its topline - analysts estimate it could be over 30% of US sales – the firm rang in the highest-ever revenues, profit before tax and EBITDA (earnings before interest, taxes, depreciation, and amortization) in a quarter driven largely by the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Atara Does An About Face As FDA Lifts Ebvallo Hold

 
• By Alaric DeArment

The biotech said it will have a type A meeting with the agency to resubmit for the cell therapy’s approval in EBV+ PTLD.